Oncternal Therapeutics, Inc. announced the receipt of a 'Study May Proceed' letter from the U.S. Food and Drug Administration (FDA), 30 days after submitting its Investigational New Drug (IND) application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin's lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.21 USD | +1.21% | +4.36% | -14.12% |
09/05 | Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
09/05 | Oncternal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.12% | 2.69Cr | |
+67.53% | 6.29TCr | |
-0.77% | 4.14TCr | |
+45.66% | 4.04TCr | |
-10.72% | 2.76TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.89TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.23TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma